Advertisement

Cali molecular diagnostics maker CardioDx files initial paperwork for an initial public offering worth up to $86.3 million.

CardioDx IPO may fetch $86.3 million

CardioDx is planning something big, although it hasn't released the full details of its upcoming initial public offering. The Palo Alto, Calif.-based genetic testing company filed preliminary documents for a maximum aggregate offering of up to $86.3 million.

CardioDx hasn't yet released details of the offering, so the number of shares and individual pricing remains a mystery, but the company has laid out its plans for how it'll spend the money it hopes to raise.

Advertisement
Advertisement